Tag: safety

– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development –

Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases.

Jacksonville, FL, June 17, 2025 (GLOBE NEWSWIRE) -- Weight loss is a humongous challenge that many people struggle with. Lack of motivation to continue a healthy lifestyle, diet, exercise, and hormonal imbalance, pave the path for weight loss supplements for an obese person. SlimJaro emerged as a trending fruitful and healthy weight loss product. It offers the perfect blend of natural ingredients, providing sustainable, long-lasting, and safe results.

Company Announcement

SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of  engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted CERo’s Orphan Drug Designation (ODD) for the company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia (AML). CER-1236 is an innovative therapy that engineers a cancer patient's own T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells.